• Mashup Score: 20

    ABSTRACT. Leukemic masses are a known complication in patients with hematologic malignancies. Here we present a case regarding a patient with recently diagnosed B-acute lymphoblastic leukemia (B-ALL) who presented with multiple sites of extramedullary involvement including an anterior mediastinal mass. This mass persisted despite multiple rounds of multiagent cytotoxic therapy. In this report, we summarize the literature regarding mediastinal masses in the setting of B-ALL and illustrate that such masses in patients with leukemias may have surprising etiology, separate from the primary disease.

    Tweet Tweets with this article
    • ๐Ÿ‘‰ Check out our report in @JIPOEditors led by Dr @LuanPhanMD - time to brush up on your DDX for a mediastinal mass - what are your top entities on your differential for thinking ๐Ÿค” about #mediastinalmasses ? Do you have a #pneumonic ? #meded @mtmdphd https://t.co/x603QFrugp https://t.co/qvWZqxU54O

  • Mashup Score: 0

    JQSH Learning Corner | Global Journal on Quality and Safety in Healthcare JQSH Quality and Safety Learning Corner The JQSH Quality and Safety Learning Corner is educational platform for those are interested in building their knowledge and resources for use in the quality and safety implementation sciences. This special section includes short articles with useful information on the concepts, methodology, and tools…

    Tweet Tweets with this article
    • The learning corning at #JQSH has many useful tools and concepts written in concise way. #quality #healthcare https://t.co/MoVL84Bfy1

  • Mashup Score: 39

    ABSTRACTIntroduction. Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients with rare solid tumors.Methods. We conducted a phase 2 basket trial that included patients with rare, advanced tumors. Patients were enrolled in the study in nine tumor-specific and a 10th cohort of miscellaneous rare histologies. Patients received pembrolizumab 200 mg intravenously every 21 days. The primary endpoint was the non-progression rate at 27 weeks per immune-related Response Evaluation Criteria in Solid Tumors (RECIST). The secondary endpoints were confirmed objective response (immune-related complete response [irCR] or partial response [irPR]), clinical benefit (irCR, irPR, or immune-related stable disease [irSD] โ‰ฅ 4 months), safety, and tolerability. Pretreatment biopsy specimens were examined for programmed cell death

    Tweet Tweets with this article
    • โญ๏ธNice to see this published ๐Ÿ‘‰๐Ÿผ #Immunotherapy in some of the rarest of the rare tumors ๐Ÿ‘‰๐ŸผPembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial @mirella_nardo @ANaingMD ๐Ÿ‘๐Ÿผ๐Ÿ‘๐Ÿผ๐Ÿ‘๐Ÿผ @DavidHongMD @OncoAlert https://t.co/7Hp6WgaVru